DPP-IV inhibitors: Beyond glycaemic control?

Trends in Cardiovascular Medicine

Volumn 24, Issue 4, 2014, Pages 157-164

  Kwok, Andrew J ^a   Mashar, Meghavi ^a   Khavandi, Kaivan ^b   Sabir, Ian ^a,b  

^a DOWNING COLLEGE   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ANIMAL; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ENZYMOLOGY; HUMAN; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84899490287     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2013.10.002     Document Type: Review

References (44)

1. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. British Medical Journal 1998, 317:703-713. UK Prospective Diabetes Study Group.
2. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
3. Ban K., Hui S., Drucker D.J., Husain M. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. Journal of the American Society of Hypertension 2009, 3:245-259.
4. Ban K., Kim K.H., Cho C.K., Sauve M., Diamandis E.P., Backx P.H., et al. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010, 151:1520-1531.
5. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
6. Bhashyam S., Fields A.V., Patterson B., Testani J.M., Chen L., Shen Y.T., et al. Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circulation: Heart Failure 2010, 3(4):512-521.
7. Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company, CAROLINA: Cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: 2000 [cited 10.10.13]. NLM Identifier: NCT01243424. http://clinicaltrials.gov/show/NCT01243424.
8. Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., Yellon D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151.
9. Brandt I., Lambeir A.M., Ketelslegers J.M., Vanderheyden M., Scharpe S., De M.I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clinical Chemistry 2006, 52:82-87.
10. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nature Medicine 2004, 10:858-864.
11. Cobble M.E., Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovascular Diabetology 2012, 11:6.
12. Dobrian A.D., Ma Q., Lindsay J.W., Leone K.A., Ma K., Coben J., et al. Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. American Journal of Physiology. Endocrinology and Metabolism 2011, 300:E410-E421.
13. Erdogdu O., Nathanson D., Sjoholm A., Nystrom T., Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Molecular and Cellular Endocrinology 2010, 325(1-2):26-35.
14. Fadini G.P., Boscaro E., Albiero M., Menegazzo L., Frison V., de K.S., et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010, 33:1607-1609.
15. Gomez N., Touihri K., Matheeussen V., Mendes Da C.A., Mahmoudabady M., Mathieu M., et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. European Journal of Heart Failure 2012, 14:14-21.
16. Graham D.J., Ouellet-Hellstrom R., Macurdy T.E., Ali F., Sholley C., Worrall C., et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. The Journal of the American Medical Association 2010, 304:411-418.
17. Green B.D., Hand K.V., Dougan J.E., McDonnell B.M., Cassidy R.S., Grieve D.J. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Archives of Biochemistry and Biophysics 2008, 478:136-142.
18. Hansson G.K. Atherosclerosis-an immune disease: the Anitschkov Lecture 2007. Atherosclerosis 2009, 202:2-10.
19. Hausenloy D.J., Yellon D.M. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovascular Research 2004, 61:448-460.
20. Hemmingsen B., Lund S.S., Gluud C., Vaag A., Almdal T., Hemmingsen C., et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database of Systystematic Reviews 2011, 6:CD008143.
21. Johansen O.E., Neubacher D., von E.M., Patel S., Woerle H.J. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovascular Diabetology 2012, 11:3.
22. Marney A., Kunchakarra S., Byrne L., Brown N.J. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 2010, 56:728-733.
23. Matikainen N., Manttari S., Schweizer A., Ulvestad A., Mills D., Dunning B.E., et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006, 49:2049-2057.
24. Merck, Oxford Diabetes Trials Unit, & Duke Clinical Research Institute, Sitagliptin Cardiovascular Outcome Study (0431-082 AM1) (TECOS). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: 2008 [cited 10.10.13]. NLM Identifier: NCT00790205. http://clinicaltrials.gov/show/NCT00790205.
25. Mistry G.C., Maes A.L., Lasseter K.C., Davies M.J., Gottesdiener K.M., Wagner J.A., et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. Journal of Clinical Pharmacology 2008, 48:592-598.
26. Monami M., Ahren B., Dicembrini I., Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes, Obesity & Metabolism 2013, 15:112-120.
27. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. The Journal of Clinical Investigation 1993, 91:301-307.
28. Nikolaidis L.A., Elahi D., Shen Y.T., Shannon R.P. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. American Journal of Physiology. Heart and Circulatory Physiology 2005, 289:H2401-H2408.
29. Nishikimi T., Maeda N., Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovascular Research 2006, 69:318-328.
30. Nissen S.E., Wolski K. "Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes". The New England Journal of Medicine 2007, 356:2457-2471.
31. Noda Y., Miyoshi T., Oe H., Ohno Y., Nakamura K., Toh N., et al. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report. Cardiovascular Diabetology 2013, 12:8.
32. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Non-fasting triglycerides and risk of for myocardial infarction and death among women and men. Ugeskrift for Laeger 2007, 169:3865-3868.
33. Ogawa S., Ishiki M., Nako K., Okamura M., Senda M., Mori T., et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. The Tohoku Journal of Experimental Medicine 2011, 223:133-135.
34. Pons J., Lee E.W., Li L., Kitlinska J. Neuropeptide Y: multiple receptors and multiple roles in cardiovascular diseases. Current Opinion in Investigational Drugs 2004, 5:957-962.
35. Read P.A., Khan F.Z., Heck P.M., Hoole S.P., Dutka D.P. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circulation. Cardiovascular Imaging 2010, 3:195-201.
36. Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England Journal of Medicine 2013, 369(14):1317-1326.
37. Ta N.N., Schuyler C.A., Li Y., Lopes-Virella M.F., Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. Journal of Cardiovascular Pharmacology 2011, 58:157-166.
38. Tomas E., Habener J.F. Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends in Endocrinology and Metabolism 2010, 21:59-67.
39. Tremblay A.J., Lamarche B., Deacon C.F., Weisnagel S.J., Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes, Obesity & Metabolism 2011, 13:366-373.
40. Vilsboll T., Krarup T., Deacon C.F., Madsbad S., Holst J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50:609-613.
41. White W.B., Cannon C.P., Heller S.R., Nissen S.E., Bergenstal R.M., Bakris G.L., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. The New England Journal of Medicine 2013, 369:1327-1335.
42. Woods R.L. Cardioprotective functions of atrial natriuretic peptide and B-type natriuretic peptide: a brief review. Clinical and Experimental Pharmacology and Physiology 2004, 31:791-794.
43. 2+ currents via activation of the cAMP-dependent protein kinase A pathway. Cardiovascular Diabetology 2011, 10:6.
44. Xiao-Yun X., Zhao-Hui M., Ke C., Hong-Hui H., Yan-Hong X. Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation. Medical Science Monitor 2011, 17(2):BR35-BR41.